Health Vidya

These highlights do not include all the information needed to use GARZULYS safely and effectively. See full prescribing information for GARZULYS. GARZULYS™ (insulin aspart-fsan) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2026 GARZULYS (insulin aspart-fsan) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Garzulys has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to NOVOLOG (insulin aspart).